CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

NCT07413757 | Recruiting

• 1 other identifier: D5161R00072
• Study Type: observational
• Target: 590
• Locations: 1 country
• Sites: 1

Brief Summary

This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.

Conditions

Non-Small Cell Lung Cancer

Keywords

NSCLC;patients and physicians;survey;EGFR-TKI;patient preference;physician preference

Outcome Measures

Primary Outcomes (2)

• Preferences weights for each attribute level evaluated in the DCE

  Preference weights will be estimated for each attribute level included in the DCE where a more positive preference weight indicates a stronger preference for the attribute level. The preference weights allow for comparison for relative preference for levels within the same attribute.

  Day of interview/survey completion(Day1)

• Relative attribute importance (RAI)

  The importance measure will be used to evaluate the preferences among treatment attributes. This measure will be calculated by using the difference of utility scores between the most and least preferred levels within an attribute. Then, this measure will divide by the summation of the difference of all tested attributes.

  Day of interview/survey completion(Day1)

Secondary Outcomes (3)

• Maximum acceptable risks (MAR) and minimum acceptable benefit (MAB)

  Day of interview/survey completion(Day1)

• RAI, MAR, and MAB by patient and physician characteristics subgroups

  Day of interview/survey completion(Day1)

• Odds ratios (ORs) for the association between patient characteristics and the likelihood of physicians recommending combination therapy (EGFR-TKI plus platinum/pemetrexed chemotherapy or EGFR-TKI plus bispecific antibody) versus EGFR-TKI monotherapy

  Day of interview/survey completion(Day1)

Study Arms (2)

Physicians group

Physicians who have experience in the treatment and management of stage IV NSCLC patients with 1L EGFR-TKI.

Patinet group

Patients receiving or who have received 1L EGFR-TKI treatment for stage IV NSCLC

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study population will include patients receiving or who have received 1L EGFR-TKI treatment for stage IV NSCLC and physicians who have experience in the treatment and management of stage IV NSCLC patients with 1L EGFR-TKI. To improve the sample representativeness and generalizability, some soft quotas may be applied during sampling. All the participants who met inclusion criteria will be included.

You may qualify if:

• Patient:
• Provide informed consent
• years or older
• Diagnosed with stage IV NSCLC
• Currently receiving or previously received 1L EGFR-TKI treatment
• Without communication barrier
• Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter
• Physician:
• Provide informed consent
• Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
• Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
• Holding the title of associate chief physician or higher
• Patient:
• Provide informed consent
• years or older

You may not qualify if:

• Not applicable.

Sponsors & Collaborators

• AstraZeneca: lead

Study Sites (1)

Research Site

Chengdu, 610000, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

AstraZeneca Clinical Study Information Center

CONTACT

1-877-240-9479; information.center@astrazeneca.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 9, 2026
• First Posted: February 17, 2026
• Study Start: March 2, 2026
• Primary Completion (Estimated): July 31, 2026
• Study Completion (Estimated): July 31, 2026
• Last Updated: April 22, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share
• Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• Access Criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Locations

CN (1)